Geode Capital Management LLC Boosts Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Geode Capital Management LLC boosted its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 4.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 218,544 shares of the company’s stock after acquiring an additional 10,032 shares during the period. Geode Capital Management LLC owned 1.04% of USANA Health Sciences worth $12,623,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Oxford Asset Management LLP bought a new stake in USANA Health Sciences during the 4th quarter worth approximately $1,072,000. Jane Street Group LLC bought a new stake in USANA Health Sciences during the 4th quarter worth approximately $494,000. Norges Bank bought a new stake in USANA Health Sciences during the 4th quarter worth approximately $16,665,000. Bank of Montreal Can raised its stake in USANA Health Sciences by 32.5% during the 4th quarter. Bank of Montreal Can now owns 2,024 shares of the company’s stock worth $159,000 after acquiring an additional 497 shares during the period. Finally, Robeco Institutional Asset Management B.V. raised its stake in USANA Health Sciences by 19.0% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 87,889 shares of the company’s stock worth $5,077,000 after acquiring an additional 14,047 shares during the period. Institutional investors own 53.31% of the company’s stock.

In other news, insider Daniel A. Macuga sold 4,599 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $84.22, for a total transaction of $387,327.78. Following the completion of the sale, the insider now directly owns 1,552 shares of the company’s stock, valued at $130,709.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Walter Noot sold 9,571 shares of the business’s stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $88.77, for a total transaction of $849,617.67. Following the sale, the chief operating officer now directly owns 9,571 shares of the company’s stock, valued at $849,617.67. The disclosure for this sale can be found here. Insiders sold 680,163 shares of company stock worth $55,104,214 in the last 90 days. 45.40% of the stock is currently owned by company insiders.

A number of equities research analysts have commented on USNA shares. Zacks Investment Research upgraded shares of USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $94.00 target price on the stock in a research note on Thursday, June 18th. ValuEngine cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, Tigress Financial reiterated a “buy” rating on shares of USANA Health Sciences in a research report on Tuesday, May 12th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. USANA Health Sciences has an average rating of “Buy” and a consensus price target of $76.00.

Shares of USNA opened at $71.56 on Wednesday. The company’s fifty day moving average is $80.61 and its 200 day moving average is $74.59. USANA Health Sciences, Inc. has a fifty-two week low of $43.01 and a fifty-two week high of $90.94. The stock has a market capitalization of $1.44 billion, a PE ratio of 15.42 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, April 21st. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.66. USANA Health Sciences had a net margin of 9.76% and a return on equity of 30.09%. The company had revenue of $266.62 million for the quarter, compared to analysts’ expectations of $220.40 million. During the same quarter in the previous year, the business posted $1.01 earnings per share. USANA Health Sciences’s quarterly revenue was down 2.3% on a year-over-year basis. Analysts anticipate that USANA Health Sciences, Inc. will post 4.89 earnings per share for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Recommended Story: Diversification in Investing

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.